Key facts
- Notable investors include Suzhou Oriza Holdings Corporation, Ennovation Ventures, Med-Fine Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Yun Ho Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Yun Ho Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yun Ho Bio
Developer of AI-assisted biopharmaceutical technologies designed for extrahepatic siRNA drug discovery and development. The company offers intelligent target identification, siRNA sequence optimization, predictive modeling, experimental design, data analysis, and therapeutic validation, thereby helping accelerate the development of safer and more effective treatments for extrahepatic diseases.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Yun Ho Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yun Ho Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yun Ho Bio in its N-PORT filings yet. We sweep new filings monthly.